Navigation Links
Navitas Names Dr. Dean Gesme as Medical Director
Date:10/17/2007

DENVER, Oct. 17 /PRNewswire/ -- Navitas Cancer Rehabilitation Centers of America, Inc. (Navitas), the market leader in providing integrated and comprehensive cancer rehabilitation services, is pleased to announce the appointment of Dean H. Gesme, Jr., M.D. as Corporate Medical Director.

In addition to currently providing care as a medical oncologist in the Minneapolis/St. Paul area, Dr. Gesme has served as the Past-Chair of the National Coalition for Cancer Survivorship and is Past-Chair of the Clinical Practice Committee of the American Society of Clinical Oncology. He has been the Oncology Representative on the AMA CPT Advisory Panel dealing with physician coding, and payment issues. Dr. Gesme is board certified in Internal Medicine, Medical Oncology, and Medical Management. Dr. Gesme attended medical school at the University of Iowa and completed his residency training in Internal Medicine in San Francisco and his fellowship in Medical Oncology at the University of Minnesota.

"Navitas has a tremendous opportunity to serve cancer survivors and Dr. Gesme is perfectly suited to provide medical leadership to this vision," shared Paul Barnes, Ph.D., President and CEO for Navitas. "Dean has devoted his career to the patient advocacy community as well to the treatment of cancer patients. We are fortunate to have him join our management team at Navitas.

"I have been impressed by the clinical basis of the cancer rehabilitation program at Navitas," Dr. Gesme stated. "I look forward to the day where rehabilitation services for cancer patients are as much the standard of care as is true for cardiac and other areas of medicine. Cancer patients deserve no less. I look forward to contributing to the clinical research efforts at Navitas to make that happen."

About Navitas Cancer Rehabilitation Centers of America

Founded in 2003, Navitas Cancer Rehabilitation Centers of America (http://www.navitasinc.com) developed an evidence-based approach to providing rehabilitation and supportive therapies to people with cancer. Navitas provides these services on a free-standing basis as well as through community-based and hospital-based oncology centers and practices. The Navitas vision is to make supportive and rehabilitation services a standard component of the cancer treatment plan through the development of a robust, multi-disciplinary clinical program and demonstrated outcomes for patients and physicians. Navitas is headquartered in Denver, Colorado.

http://www.navitasinc.com

Media Contact:

Shaun Burns

303-865-7840

sburns@navitasinc.com


'/>"/>
SOURCE Navitas Cancer Rehabilitation Centers of America
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Wisconsin IT association names Gee president, CEO
2. Quintessence Biosciences names new president
3. CDW names VP to handle Berbee merger
4. NimbleGen names CFO with capital-raising past
5. Cisco names Berbee a top partner of 2005
6. Cisco names Inacom most innovative partner
7. UW-Madison medical school names new dean
8. GE Healthcare names new CEO
9. Bruker AXS names new leadership
10. Sonic Foundry names new senior vice president
11. MyWeather names new president, marketing officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):